Insight Molecular Diagnostics Inc.IMDX
Key ratios
FCF / Sales
-625.6%2025
2024
-1127.3%2023
-1570.6%
ROA
-62.7%2025
2024
-26.4%2023
-15.9%
ROE
-910.9%2024
2023
-76.3%
Revenue growth
115.6%2025
2024
25.2%2023
56.9%
Recent news
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
Track IMDX in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer